| Dr Vinay M Patel, MD | |
|
708 Goodlette-frank Rd N Fl 2, Naples, FL 34102-5644 | |
| (239) 291-7005 | |
| (239) 241-6284 |
| Full Name | Dr Vinay M Patel |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 16 Years |
| Location | 708 Goodlette-frank Rd N Fl 2, Naples, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568621407 | NPI | - | NPPES |
| 17V72 | Other | FL | BCBS |
| 011981800 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | ME118851 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trilogy Home Healthcare | Estero, FL | Home health agency |
| Naples Community Hospital | Naples, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Meliora Healthcare Pllc | 6204297237 | 4 |
| Nchmd Inc | 9436139565 | 374 |
News Archive
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.
The cortical response to esophageal, stomach or rectal stimulation has been studied using several different modalities including evoked potentials, functional magnetic resonance imaging (fMRI), and positron emission tomography. However, there is no information concerning the cerebral cortical response to sensory signals that originate in the biliary tract in humans.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
› Verified 9 days ago
| Entity Name | Bay Area Chest Physicians P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972584829 PECOS PAC ID: 0941299010 Enrollment ID: O20040512000671 |
News Archive
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.
The cortical response to esophageal, stomach or rectal stimulation has been studied using several different modalities including evoked potentials, functional magnetic resonance imaging (fMRI), and positron emission tomography. However, there is no information concerning the cerebral cortical response to sensory signals that originate in the biliary tract in humans.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
› Verified 9 days ago
| Entity Name | Nchmd Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831120195 PECOS PAC ID: 9436139565 Enrollment ID: O20040721000254 |
News Archive
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.
The cortical response to esophageal, stomach or rectal stimulation has been studied using several different modalities including evoked potentials, functional magnetic resonance imaging (fMRI), and positron emission tomography. However, there is no information concerning the cerebral cortical response to sensory signals that originate in the biliary tract in humans.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
› Verified 9 days ago
| Entity Name | Meliora Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821793597 PECOS PAC ID: 6204297237 Enrollment ID: O20230807002421 |
News Archive
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.
The cortical response to esophageal, stomach or rectal stimulation has been studied using several different modalities including evoked potentials, functional magnetic resonance imaging (fMRI), and positron emission tomography. However, there is no information concerning the cerebral cortical response to sensory signals that originate in the biliary tract in humans.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vinay M Patel, MD 708 Goodlette-frank Rd N Fl 2, Naples, FL 34102-5644 Ph: (239) 291-7005 | Dr Vinay M Patel, MD 708 Goodlette-frank Rd N Fl 2, Naples, FL 34102-5644 Ph: (239) 291-7005 |
News Archive
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.
Aptuit, Inc., today announced that it has developed a proprietary production screen to enable a better understanding of active pharmaceutical ingredients (API) and drug formulations earlier in the product lifecycle. The production screen applies advanced theoretical developments in solid-state chemistry to address challenges at the most critical interfaces in the drug development process.
The cortical response to esophageal, stomach or rectal stimulation has been studied using several different modalities including evoked potentials, functional magnetic resonance imaging (fMRI), and positron emission tomography. However, there is no information concerning the cerebral cortical response to sensory signals that originate in the biliary tract in humans.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
› Verified 9 days ago
Ricardo Martinez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 851 5th Ave N Ste 102, Naples, FL 34102 Phone: 239-315-7801 Fax: 855-888-3291 | |
Dr. Karen Moss Ezrine, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 762 Regency Reserve Cir, Naples, FL 34119 Phone: 239-354-1998 | |
Dr. Lawrence Kenneth Harris, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2171 Pine Ridge Rd, Suite F, Naples, FL 34109 Phone: 239-566-7425 Fax: 239-593-3430 | |
Todd David Brodie, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 730 Goodlette Rd N, Ste 205, Naples, FL 34102 Phone: 239-436-3666 Fax: 239-436-3678 | |
Dr. Frank Michael Elterman, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6101 Pine Ridge Rd, Naples, FL 34119 Phone: 239-330-2933 Fax: 855-691-0391 | |
Vincent Charles Bianca Iii, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 9015 Strada Stell Ct, Suite 201, Naples, FL 34109 Phone: 239-597-5638 Fax: 239-597-5628 | |
Catherine Nina Kowal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 Veterans Park Dr, Suite 103, Naples, FL 34109 Phone: 239-596-5220 Fax: 239-643-9816 |